Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Gain on sale of PREBOOST® business

Impairment of intangible assets

Provision for (recovery of) credit losses

Gain on sale of ENTADFI® assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veru

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Veru reports positive Phase III results for sabizabulin in COVID-19

Veru's positive Phase III trial results for sabizabulin in COVID-19 highlight its potential in reducing mortality.
Financially, challenges persist with decreased revenues and increased expenses, but the company is focused on growth strategies.
The company's strengths lie in sabizabulin's unique mechanism, clinical trial prioritization, and revenue generation plans.
Opportunities for Veru include commercializing sabizabulin, driving revenue growth, and advancing oncology trials.

Veru reports Q2 financial challenges but shows promise in clinical developments

Veru Inc. faced financial challenges in Q2 2023 with decreased net revenues and significant operating losses, prompting efforts to manage costs and explore strategic options.
Despite the financial hurdles, the company demonstrated strengths in clinical developments, securing additional funding, and pursuing growth opportunities in breast cancer and viral ARDS treatments.
Veru's focus on increasing revenues through marketing efforts, expanding distribution channels, and seeking strategic partnerships positions the company for future growth and success in the pharmaceutical industry.

Veru reports mixed Q3 results, eyes partnerships and market expansion

Veru Inc. faced challenges with a decrease in net revenues but achieved a net income for Q3 2023.
Strengths lie in promising results of enobosarm and sabizabulin studies, FDA clarity, and improved cash position.
Opportunities include expanding evaluation of sabizabulin, seeking partnerships, and market expansion through tenders.
The company needs to address challenges of net losses, high operating expenses, and maintaining adequate cash reserves.

Veru Inc. reports Q4 earnings, pursues partnerships for drug development

Veru Inc. reported a decrease in net revenues but secured significant funding through a successful public offering. Their drug development program, particularly enobosarm and sabizabulin, holds promise for multiple medical applications. The pursuit of partnerships and the potential for combination treatments present opportunities for future growth.

Veru Inc. reports Q1 growth, seeks partners for enobosarm study

Veru Inc. demonstrates financial progress and strategic initiatives in drug development, positioning itself for future growth and innovation.
The company's focus on enobosarm's potential in weight loss and oncology, along with seeking partnerships, reflects a proactive approach to advancing its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

San Francisco, California--(Newsfile Corp. - December 9, 2022) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now.Class Period: May 11, 2022 - Nov. 9, 2022Lead Plaintiff Deadline: Feb. 6, 2023Visit: www.hbsslaw.com/investor-fraud/VERU Contact An Attorney Now: VERU@hbsslaw.com 844-916-0895Veru Inc.

VERU CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed

LOS ANGELES--( BUSINESS WIRE )--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) investors concerning the Company's possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Veru Inc. (VERU) on Behalf of Investors

SAN DIEGO , Dec. 7, 2022 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Veru Inc. (NASDAQ: VERU) common stock between May 11, 2022 and November 9, 2022, inclusive (the "Class Period") have until February 6, 2023 to seek appointment as lead plaintiff in the Veru class action lawsuit. Captioned Ewing v.

INVESTOR NOTICE: Veru Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - VERU

NEW YORK--( BUSINESS WIRE )--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Veru, Inc. (NASDAQ: VERU) between May 11, 2022 and November 9, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than February 3, 2022.

EQUITY ALERT: Rosen Law Firm Encourages Veru, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action– VERU

BENSALEM, Pa.--( BUSINESS WIRE )--Law Offices of Howard G. Smith announces an investigation on behalf of Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) investors concerning the Company's possible violations of federal securities laws.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Veru Inc. (VERU) on Behalf of Investors

LOS ANGELES--( BUSINESS WIRE )--The Law Offices of Frank R. Cruz announces an investigation of Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Announces Investigation of Veru Inc. (VERU) on Behalf of Investors

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Veru Inc. (“Veru” or “the Company”) (NASDAQ: VERU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Files Class Action on Behalf of Investors in Veru Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 6, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Veru Inc. ("Veru" or "the Company") (NASDAQ:VERU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 11, 2022 and November 9, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before February 3, 2023.

INVESTOR DEADLINE NOTICE: The Schall Law Firm Files Class Action on Behalf of Investors in Veru Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm

NEW YORK--( BUSINESS WIRE )--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) in the United States Southern District Court of Florida on behalf of all persons and entities who purchased or otherwise acquired Veru securities between May 11, 2022 and November 9, 2022, both dates inclusive (the “Class Period”). Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

VERU ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm

SAN DIEGO--( BUSINESS WIRE )-- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Veru Inc. (NASDAQ: VERU) common stock between May 11, 2022 and November 9, 2022, inclusive (the “Class Period”) have until February 6, 2023 to seek appointment as lead plaintiff in the Veru class action lawsuit. Captioned Ewing v. Veru Inc., No. 22-cv-23960 (S.D. Fla.), the Veru class action lawsuit charges Veru and certain of its top executives with violations of the Securities Exchange Act of 1934.

INVESTOR ALERT: Veru Inc. Investors with Substantial Losses Have Opportunity to Lead the Veru Class Action Lawsuit - VERU

SAN DIEGO--( BUSINESS WIRE )--The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Veru Inc. (NASDAQ: VERU) common stock between May 11, 2022 and November 9, 2022, for violations of the Securities Exchange Act of 1934. Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers, and also develops medicines for COVID-19 and other diseases related to viral and acute respiratory distress syndrome ("ARDS").

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Veru Inc. (VERU)

SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in Veru Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm

NEW YORK , Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. ("Veru" or the "Company") (NASDAQ: VERU). Such investors are advised to contact Robert S.

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Veru Inc. (NASDAQ:VERU ) Q4 2022 Earnings Conference Call December 5, 2022 8:00 AM ET Company Participants Brandon Folkes - Cantor Fitzgerald Leland Gershell - Oppenheimer Chris Howerton - Jefferies Yi Chen - H.C. Wainwright Conference Call Participants Sam Fisch - Executive Director, Investor Relations, and Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer and President Michele Greco - Chief Financial Officer and Chief Administrative Officer Operator Good morning ladies and gentlemen, and welcome to Veru Inc.'s Investor Conference Call.

Veru Inc. (VERU) Q4 2022 Earnings Call Transcript

Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates

U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

Is Veru a Buy?

NEW YORK , Nov. 30, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Veru Inc. (NASDAQ: VERU) resulting from allegations that Veru may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Veru securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Veru Inc. Investors to Inquire About Securities Class Action Investigation - VERU

MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Monday, December 5, 2022, at 8:00 a.m. ET to discuss its fiscal 2022 fourth quarter and full year ended September 30, 2022 financial results and provide a business update.

Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022

The negative impact of its COVID-19 program faltering will soon be in the past.

Is It Too Late to Buy Veru Stock?

New York, New York--(Newsfile Corp. - November 23, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Veru Inc. (NASDAQ: VERU) resulting from allegations that Veru may have issued materially misleading business information to the investing public.

ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Veru Inc. Investors to Inquire About Securities Class Action Investigation - VERU

Boston, Massachusetts--(Newsfile Corp. - November 22, 2022) - Block & Leviton is investigating Veru Corp. (NASDAQ: VERU) for potential securities law violations. Investors who have lost money in their Veru investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/veru.What is this all about?On November 10, 2022, Veru. Inc.

VERU, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Investors are concerned that approval for a COVID-19 therapy will be delayed or denied.

Why Shares of Veru Fell 10.33% on Monday

San Francisco, California--(Newsfile Corp. - November 17, 2022) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now. The firm is investigating possible securities law violationsVisit: www.hbsslaw.com/investor-fraud/VERU Contact An Attorney Now: VERU@hbsslaw.com 844-916-0895Veru Inc. (NASDAQ: VERU) Investigation: The investigation focuses on Veru's past statements concerning the development of its orally administered COVID-19 drug, sabizabulin. More specifically, in Apr. 2022,

VERU INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Veru Inc. (VERU) Investors with Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

NEW YORK , Nov. 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Veru Inc. (NASDAQ: VERU) resulting from allegations that Veru may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Veru securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

VERU BREAKING NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Veru Inc. Investors to Inquire About Securities Class Action Investigation - VERU

News for Veru Stock (VERU)